A Novel Intervention for Patients With Cancer
Launched by DANA-FARBER CANCER INSTITUTE · Dec 1, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to help cancer patients manage psychological symptoms, such as difficult thoughts and feelings, that they may experience during their treatment. The study uses a method called Acceptance and Commitment Therapy (ACT), which involves working with a licensed psychologist over six sessions. It is designed to support patients who are at risk of misusing opioids, which are often prescribed for cancer pain. The goal is to see how well this new approach works and if patients find it helpful.
To participate in this trial, individuals must be at least 18 years old, have a cancer diagnosis, and be expected to live for at least six more months. They also need to show some risk for opioid misuse based on a specific screening tool. Participants will fill out questionnaires and have a follow-up interview after the study. This trial is currently recruiting patients of all genders and aims to ensure that those who join can actively engage in the therapy and assessments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • at least 18 years old
- • have an estimated survival time of at least 6 months (as estimated by palliative care provider)
- • score at least 4 on the Opioid Risk Tool (ORT)
- • have been diagnosed with any cancer, including hematologic malignancies
- • performance status criterion of 0, 1, or 2 \[ with 0 indicating that the patient is asymptomatic, 1 that the patient is symptomatic but fully ambulatory, and 2 that the patient is symptomatic and in bed \<50% of the day\]
- Exclusion Criteria:
- • Patients with a score at least 3 to ensure that all enrolled patients are able to participate in the intervention, complete assessments, ensure that no patients who are too sick to participate are enrolled; this will enhance the rigor of the study)
- • currently be on opioid therapy
- • not meet criteria for current substance use disorder
- • assessed by the Diagnostic \& Statistical Manual of mental disorders; DSM-5 or be receiving substance use disorder treatment; and speak and comprehend English sufficiently to be able to participate in psychotherapy.
About Dana Farber Cancer Institute
The Dana-Farber Cancer Institute is a premier cancer research and treatment institution located in Boston, Massachusetts. Renowned for its commitment to advancing cancer care through innovative research, the institute integrates cutting-edge clinical trials with a multidisciplinary approach to patient care. With a focus on translating scientific discoveries into effective therapies, Dana-Farber collaborates with a network of leading researchers and healthcare professionals to improve outcomes for patients with cancer. The institute’s dedication to education, advocacy, and community engagement further underscores its mission to eradicate cancer and enhance the quality of life for those affected by the disease.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Patients applied
Trial Officials
Miryam Yusufov, PhD
Principal Investigator
Dana-Farber Cancer Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials